Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update

• Topline results in the previously treated EGFR cohort (cohort 1) of
  the poziotinib ZENITH20 trial are expected in Q4 2019.
• Integrated data from the two Phase 3 ROLONTIS^®
  (eflapegrastim) clinical trials will be presented in a poster session
  at the American Society of Clinical Oncology 2019 annual meeting.
  Spectrum is working on filing the ROLONTIS Biologics License
  Application (BLA) as soon as possible.
• Spectrum completed an asset purchase and licensing deal for the
  Focused Interferon Therapeutics (FIT) platform and two novel, early
  stage assets.
• Divestiture of Spectrum’s seven FDA-approved legacy products closed in
  Q1 2019 and triggered an up-front cash payment of $158.8 million.

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical
company focused on novel and targeted oncology therapies, announced
today financial results for the three-month period ended March 31, 2019.

“We are well on our way to fully executing our strategy for Spectrum,”
said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “The Q1
sale of our portfolio of legacy oncology products provided cash and
allowed us to focus on our late-stage assets as well as new growth
opportunities. Earlier today, we announced the acquisition of two new
assets and a novel antibody-interferon fusion technology platform that
could have broad application in oncology. With key near-term catalysts
for poziotinib and ROLONTIS and two newly acquired assets, we are
building a robust oncology pipeline.”

Pipeline Overview

Poziotinib, an irreversible tyrosine kinase inhibitor targeting
EGFR and HER2 mutations

• Topline results from the EGFR previously treated non-small cell lung
  cancer cohort (cohort 1) in the ZENITH20 trial are expected in Q4
  2019; data from cohort 1 are intended to support a New Drug
  Application (NDA) filing with the FDA.
• Enrollment for the HER2 previously treated non-small cell lung cancer
  cohort (cohort 2) is progressing ahead of previous expectations that
  enrollment would be complete in Q4. This cohort also has the potential
  to support an NDA filing with the FDA in the future.

ROLONTIS (eflapegrastim), a novel long-acting GCSF

• Integrated data from the two Phase 3 ROLONTIS clinical trials (n =
  643) will be presented in a poster session at the American Society of
  Clinical Oncology 2019 annual meeting.
• Spectrum is working on filing the ROLONTIS BLA as soon as possible.

Business Development

• Spectrum completed an asset purchase and license agreement for a novel
  immuno-oncology platform and two early stage assets. Originally
  developed by scientists at UCLA and licensed to Spectrum by UCLA
  Technology Development Group, the FIT platform fuses interferon with
  various monoclonal antibodies targeting various tumor antigens and
  potentially has broad application in oncology. The license also
  includes two novel assets derived from this platform.

• The first asset is an antibody-interferon fusion molecule directed
  against CD20 (Anti-CD20-IFNá). This drug candidate is in Phase 1
  development for treating relapsed or refractory non-Hodgkin lymphoma,
  including diffuse large b-cell lymphoma patients where a considerable
  unmet medical need exists. Research for this program received
  financial support through the Therapy Acceleration Program® of The
  Leukemia & Lymphoma Society, Inc. (LLS), and an LLS research grant to
  UCLA.
• The second asset is an antibody-interferon fusion molecule directed
  against GRP94, a target for which currently there are no existing
  approved therapies. It has the potential for treating both solid and
  hematologic malignancies.

Three-Month Period Ended March 31, 2019 (All
numbers are from Continuing Operations and are approximate)

GAAP Results

Spectrum recorded a loss of $39.8 million, or a loss of $0.36 per basic
and diluted share, in the three-month period ended March 31, 2019,
compared to a loss of $19.2 million, or a loss of $0.19 per basic and
diluted share, in the comparable period in 2018. Total research and
development expenses were $21.9 million in the quarter, as compared to
$13.4 million in the same period in 2018. Selling, general and
administrative expenses were $16.0 million in the quarter, compared to
$16.6 million in the same period in 2018.

Non-GAAP Results

Spectrum recorded a non-GAAP loss of $29.2 million, or a non-GAAP loss
of $0.27 per basic and diluted share, in the three-month period ended
March 31, 2019, compared to a non-GAAP net loss of $26.8 million, or a
non-GAAP loss of $0.27 per basic and diluted share, in the comparable
period in 2018. Non-GAAP research and development expenses were $20.4
million, as compared to $12.7 million in the same period of 2018.
Non-GAAP selling, general and administrative expenses were $10.7
million, as compared to $14.3 million in the same period in 2018.

Conference Call

Thursday, May 9, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Domestic: (877) 837-3910, Conference ID# 4290388

International: (973) 796-5077, Conference ID# 4290388

This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals’ website: www.sppirx.com on May 9,
2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on
acquiring, developing, and commercializing novel and targeted drug
products, with a primary focus in hematology and oncology. Spectrum has
a strong track record of successfully executing across the
biopharmaceutical business model, from in-licensing and acquiring
differentiated drugs, clinically developing novel assets, successfully
gaining regulatory approvals, and commercializing in a competitive
healthcare marketplace. Spectrum has a late-stage pipeline with novel
assets that serve areas of unmet need. This pipeline has the potential
to transform the company in the near future.

Notice Regarding Forward-looking Statements

Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the United States
Private Securities Litigation Reform Act of 1995, as amended to date.
These forward-looking statements relate to a variety of matters,
including, without limitation, statements that relate to Spectrum’s
business and its future, the Company’s ability to execute its long-term
strategy, the timing of the BLA filing for ROLONTIS, the timing of the
topline results from the poziotinib EGFR previously treated non-small
cell lung cancer cohort in the ZENITH20 trial, the timing of enrollment
for the poziotinib HER2 previously treated non-small cell lung
cancer cohort in the ZENITH20 trial, the potential for the two
poziotinib cohorts to support an NDA filing with the FDA, the potential
clinical applications for the FIT therapies, including, in the case of
the anti-body interferon fusion molecule directed against GRP94, its
potential for treating both solid and hematologic malignancies, the
ability of the FIT therapies to meet currently unaddressed medical needs
and the size of potential markets, the future potential of Spectrum’s
existing drug pipeline, and any other statements that are not purely
statements of historical fact. These forward-looking statements
are based on management’s current beliefs, expectations and assumptions
and are subject to significant risks and uncertainties. Investors are
cautioned not to place undue reliance on any such forward-looking
statements. All such forward-looking statements speak only as of the
date they are made, and Spectrum undertakes no obligation to update or
revise these statements, whether as a result of new information, future
events or otherwise. Although Spectrum believes that the expectations
reflected in these forward-looking statements are reasonable, these
statements involve many risks and uncertainties that may cause actual
results to differ materially from what may be expressed or implied in
these forward-looking statements, including, without limitation, the
uncertainties inherent in new product development, including clinical
trial results and additional analysis of existing clinical data, the
possibility that Spectrum’s applications to the FDA and other regulatory
agencies may not receive approval in a timely manner or at all, the
possibility that Spectrum’s existing and new drug candidates, including
poziotinib, ROLONTIS and the FIT therapies, may not be more effective,
safer or more cost efficient than competing drugs, and Spectrum’s
dependence on third parties for clinical trials, manufacturing and
quality control. For a further discussion of risks and uncertainties
that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the business of
Spectrum in general, see the risk disclosures in the Annual Report on
Form 10-K of Spectrum for the year ended December 31, 2018, and in
subsequent reports on Forms 10-Q and 8-K and other filings made with the
SEC by Spectrum.

SPECTRUM PHARMACEUTICALS, INC.^® and ROLONTIS^®
are registered trademarks of Spectrum Pharmaceuticals, Inc and
its affiliates. REDEFINING CANCER CARE™ and the Spectrum
Pharmaceuticals’ logos are trademarks owned by Spectrum Pharmaceuticals,
Inc. Any other trademarks are the property of their respective owners.

© 2019 Spectrum Pharmaceuticals, Inc. All Rights Reserved

SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited)
		Three Months Ended March 31,
		2019				2018
Revenues		$	—			$	—
Operating costs and expenses:
Selling, general and administrative		15,952				16,616
Research and development		21,886				13,365
Total operating costs and expenses		37,838				29,981
Loss from continuing operations		(37,838		)		(29,981		)
Other (expense) income:
Interest income (expense), net		1,061				(230		)
Other (expense) income, net		(11,285		)		9,972
Total other (expense) income		(10,224		)		9,742
Loss from continuing operations before income taxes		(48,062		)		(20,239		)
Benefit for income taxes from continuing operations		8,242				1,067
Loss from continuing operations		$	(39,820	)		$	(19,172	)
Income from discontinued operations, net of income taxes		20,665				3,356
Net loss		$	(19,155	)		$	(15,816	)
Basic and diluted loss per share:
Loss per common share from continuing operations		$	(0.36	)		$	(0.19	)
Income per common share from discontinued operations		0.19				0.03
Net loss per common share		$	(0.17	)		$	(0.16	)
Weighted average shares outstanding:
Basic and Diluted		109,552,602				100,809,853

SPECTRUM PHARMACEUTICALS, INC. Income from Discontinued Operations, net of Income Taxes (In thousands) (Unaudited)
		Three Months Ended March 31,
		2019				2018
Product sales, net		$	14,183			$	28,111
License fees and service revenue		290				2,384
Total revenues		14,473				30,495
Operating costs and expenses:
Cost of sales (excluding amortization of intangible assets)		3,168				6,813
Selling, general and administrative		5,951				7,488
Research and development		2,536				4,530
Amortization of intangible assets		1,248				6,947
Restructuring – employee severance		6,297				—
Total operating costs and expenses		$	19,200			$	25,778
Loss from discontinued operations		$	(4,727	)		$	4,717
Other income (expense):
Change in fair value of contingent consideration		(1,478		)		(291		)
Gain on sale of Commercial Product Portfolio*		33,644				—
Total other income (expense)		32,166				(291		)
Income from discontinued operations before income taxes		27,439				4,426
Provision for income taxes from discontinued operations**		(6,774		)		(1,070		)
Income from discontinued operations, net of income taxes		$	20,665			$	3,356

*This pre-tax gain on sale represents the $158.8 million proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date, and after legal and banker transaction expenses for the three months ended March 31, 2019 that aggregated $3.9 million.

**This income tax provision represents an allocation of taxes as required under the intraperiod allocation guidance (see Note 10). Due to our aggregate net operating loss-carryforwards, no federal or state income tax payments are expected to be made relating to our current year activity, inclusive of our gain on sale of the Commercial Product Portfolio.

SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets (In thousands, expect per share and par value amounts) (Unaudited)
		March 31, 2019				December 31, 2018
ASSETS
Current assets:
Cash and cash equivalents		$	272,652			$	157,480
Restricted cash		4,000				—
Marketable securities		33,229				46,508
Accounts receivable, net of allowance for doubtful accounts of $67 and $67, respectively		14,936				29,873
Other receivables		7,466				3,698
Prepaid expenses and other assets		7,955				7,574
Discontinued operations, current assets		—				5,555
Total current assets		340,238				250,688
Property and equipment, net of accumulated depreciation		466				385
Other assets		8,180				7,188
Facility and equipment under lease		3,774				—
Discontinued operations, non-current assets		—				132,625
Total assets		$	352,658			$	390,886
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and other accrued liabilities		$	60,302			$	69,460
Accrued payroll and benefits		5,168				9,853
Contract liabilities		4,850				4,850
Discontinued operations, current liabilities		—				2,311
Total current liabilities		70,320				86,474
Deferred tax liabilities		—				1,469
Other long-term liabilities		9,789				5,650
Discontinued operations, non-current liabilities		—				14,031
Total liabilities		80,109				107,624
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding		—				—
Common stock, $0.001 par value; 300,000,000 shares authorized; 111,212,572 and 110,525,141 issued and outstanding at March 31, 2019 and December 31, 2018, respectively		111				110
Additional paid-in capital		895,571				886,740
Accumulated other comprehensive loss		(4,092		)		(3,702		)
Accumulated deficit		(619,041		)		(599,886		)
Total stockholders’ equity		272,549				283,262
Total liabilities and stockholders’ equity		$	352,658			$	390,886

Non-GAAP Financial Measures (from Continuing Operations)

In this press release, Spectrum reports certain historical results that
have not been prepared in accordance with generally accepted accounting
principles (GAAP), including non-GAAP selling, general and
administrative expenses, non-GAAP research and development expenses,
non-GAAP net loss and non-GAAP net loss per share. Non-GAAP financial
measures are reconciled to the most directly comparable GAAP financial
measures in the tables of this press release and the accompanying
footnotes. The non-GAAP financial measures contained herein are a
supplement to the corresponding financial measures prepared in
accordance with GAAP. The non-GAAP financial measures presented exclude
the items summarized in the below table.

Management believes that adjustments for these items assist investors in
making comparisons of period-to-period operating results and that these
items are not indicative of the company’s on-going core operating
performance. Management uses non-GAAP net income (loss) in its
evaluation of the company’s core after-tax results of operations and
trends between fiscal periods and believes that these measures are
important components of its internal performance measurement process.
Management believes that these non-GAAP financial measures are useful to
investors in providing greater transparency to the information used by
management in its operational decision-making. Management believes that
the use of these non-GAAP financial measures also facilitates a
comparison of the Company’s underlying operating performance with that
of other companies in its industry, which use similar non-GAAP measures
to supplement their GAAP results.

The non-GAAP financial measures presented herein have certain
limitations in that they do not reflect all of the costs associated with
the operations of the company’s business as determined in accordance
with GAAP. Therefore, investors should consider non-GAAP financial
measures in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP. In
addition, other companies, including other companies in our industry,
may calculate non-GAAP financial measures differently than we do,
limiting their usefulness as a comparative tool. Investors and potential
investors are encouraged to review the reconciliation of our non-GAAP
financial measures contained within this news release with our GAAP
financial results.

SPECTRUM PHARMACEUTICALS, INC. Reconciliation of Non-GAAP Adjustments for Condensed Consolidated Statements of Operations (In thousands, expect per share amounts)
					CONTINUING OPERATIONS ONLY Three Months Ended March 31,
					2019				2018
(1	)		GAAP selling, general and administrative		$	15,952			$	16,616
			Non-GAAP adjustments to SG&A:
			Severance expense		(1,641		)		—
			Stock-based compensation expense		(3,450		)		(2,253		)
			Depreciation expense		(66		)		(46		)
			Lease expense		(129		)		$	—
			Non-GAAP selling, general and administrative		$	10,666			$	14,317
(2	)		GAAP research and development		$	21,886			$	13,365
			Non-GAAP adjustments to R&D:
			Severance expense		(547		)		—
			Stock-based compensation expense		(908		)		(632		)
			Depreciation expense		(2		)		(2		)
			Non-GAAP research and development		$	20,429			$	12,731
(3	)		GAAP net loss from continuing operations		$	(39,820	)		$	(19,172	)
			Non-GAAP adjustments to net loss from continuing operations:
			Adjustments to SG&A, and R&D as noted above		6,743				2,933
			Adjustments to other (expense) income		12,140				(9,542		)
			Adjustments to benefit for income taxes		(8,243		)		(1,067		)
			Non-GAAP net loss from continuing operations		$	(29,180	)		$	(26,848	)
(4	)		GAAP net loss from continuing operations – per share (basic and diluted)		$	(0.36	)		$	(0.19	)
			Non-GAAP net loss from continuing operations – per share (basic and diluted)		$	(0.27	)		$	(0.27	)
			Weighted average shares outstanding:
			Basic		109,552,602				100,809,853
			Diluted		109,552,602				100,809,853

(1) Non-GAAP selling, general and
administrative expenses (from continuing operations): These
amounts reflect adjustments to reverse allocated operating expenses for
certain non-cash items (including stock-based compensation, depreciation
and lease expense), as well as the reversal of non-recurring severance
expenses. We believe the resulting non-GAAP SG&A value is more
indicative of the period-over-period success of our administrative
expense control, and more reflective of our normalized SG&A expense
trends.

(2) Non-GAAP research and development expenses
(from continuing operations): These amounts reflect
adjustments to reverse allocated operating expenses for certain non-cash
items (including stock-based compensation and depreciation), as well as
non-recurring severance expenses. We believe the resulting non-GAAP R&D
value is more reflective of our true R&D expense trends.

(3) Non-GAAP net loss (from continuing
operations): These amounts reflect all non-GAAP adjustments
described in (1) through (2) above, plus other non-cash and/or
non-recurring items, including: (i) adjustments to reverse the impact of
income taxes; (ii) reversal of foreign exchange gains and losses
(non-cash); (iii) reversal of debt discount accretion expense (non-cash)
for our convertible notes during the prior year period; and (iv)
reversal of the mark-to-market adjustment on our equity securities.

(4) Non-GAAP net loss per share (from
continuing operations): These amounts reflect all non-GAAP
adjustments in (1) through (3) above to present our overall non-GAAP
financial results for each period on a per-share basis.

Contacts

Shiv Kapoor
Vice President, Strategic Planning & Investor Relations
702-835-6300
[email protected]